$AKBA this new license agreement will pump $CYCN but not really us over here. It looks like we're trying to position as a full spectrum CKD pharma though. We've got the marketing team that need to be busier w/ Auryxia challenges. I like it though. Haven't fully dove into Praliciguat but the surface of it looks great.